Cancer Family
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
CI-CAN-00000175Explore in graph →
Non-malignant81 active trials1 approved drugs18 evidence items
- NCIt
- C27291
Loading cancer entity…
Cancer Family
CI-CAN-00000175Explore in graph →
Clinical trials
253 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06441331 | Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors(KinLET) | recruiting | Phase 1 | 20 | ITM Solucin GmbHINDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT07194044 | Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes(METTSEO) | recruiting | Phase 1 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER |
| 1 |
| Sep 25, 2026 |
| clinicaltrials |
| NCT07297979 | Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS) | recruiting | Phase 1 | 50 | AmgenINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT06926283 | A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors | recruiting | Phase 1 | 110 | Hangzhou DAC Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07830667 | A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat | not yet recruiting | Phase 1 / Phase 2 | 79 | Children's Oncology GroupNETWORK | 0 | Sep 22, 2026 | clinicaltrials |
| NCT06395103 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | recruiting | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Sep 17, 2026 | clinicaltrials |
| NCT07695311 | EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT | not yet recruiting | Phase 1 | 24 | Rabi HannaOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT03715933 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | recruiting | Phase 1 | 411 | Inhibrx Biosciences, IncINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT06156410 | Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas | recruiting | Phase 1 | 30 | Children's Hospital of PhiladelphiaOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06465199 | Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas | recruiting | Phase 1 / Phase 2 | 265 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06541262 | Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 104 | Milton S. Hershey Medical CenterOTHER | 2 | Sep 3, 2026 | clinicaltrials |
| NCT05918640 | Lurbinectedin in FET-Fused Tumors(LiFFT) | recruiting | Phase 1 / Phase 2 | 63 | Children's Hospital of PhiladelphiaOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03356782 | Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas | not yet recruiting | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04433221 | Combination Immunotherapy Targeting Sarcomas | not yet recruiting | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05395741 | Regorafenib in Patients With Refractory Primary Bone Tumors(Regbone) | completed | Phase 1 / Phase 2 | 30 | Institute of Mother and Child, Warsaw, PolandOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07172958 | Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)(SABRE) | recruiting | Phase 1 | 18 | Children's National Research InstituteOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04337177 | Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | active not recruiting | Phase 1 | 20 | Valent Technologies, LLCINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03635632 | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | active not recruiting | Phase 1 | 94 | Baylor College of MedicineOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06625190 | Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | University of FloridaOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07197554 | A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 171 | SEED Therapeutics, Inc.INDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04897321 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | recruiting | Phase 1 | 48 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04901702 | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | recruiting | Phase 1 / Phase 2 | 90 | St. Jude Children's Research HospitalOTHER | 2 | May 19, 2026 | clinicaltrials |
| NCT06094101 | Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)(PerVision) | recruiting | Phase 1 / Phase 2 | 30 | University Hospital TuebingenOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04483778 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 68 | Seattle Children's HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT04308330 | Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies(NYMC195) | recruiting | Phase 1 | 30 | New York Medical CollegeOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06566092 | Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants | active not recruiting | Phase 1 | 40 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03478462 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas(CLOVER-2) | active not recruiting | Phase 1 | 30 | Cellectar Biosciences, Inc.INDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT04890093 | Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors | suspended | Phase 1 / Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06709495 | Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas | recruiting | Phase 1 / Phase 2 | 63 | David S Shulman, MDOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07222735 | Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas | recruiting | Phase 1 | 42 | St. Jude Children's Research HospitalOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT01625351 | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | completed | Phase 1 | 23 | St. Jude Children's Research HospitalOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05734066 | Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | recruiting | Phase 1 / Phase 2 | 60 | Jazz PharmaceuticalsINDUSTRY | 2 | Feb 3, 2026 | clinicaltrials |
| NCT05071209 | Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 2 | Jan 23, 2026 | clinicaltrials |
| NCT04995003 | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | recruiting | Phase 1 | 25 | Baylor College of MedicineOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05830084 | Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma(REGO-INTER-EWI) | active not recruiting | Phase 1 | 23 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 6 | Jan 6, 2026 | clinicaltrials |
| NCT01858168 | Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma | completed | Phase 1 | 49 | Massachusetts General HospitalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04067115 | SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients(U01CA236220) | completed | Phase 1 / Phase 2 | 37 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT03618381 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 44 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT03514407 | A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma | terminated | Phase 1 | 25 | Incyte CorporationINDUSTRY | 4 | Oct 21, 2025 | clinicaltrials |
| NCT02508038 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | recruiting | Phase 1 | 22 | University of Wisconsin, MadisonOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05605522 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | terminated | Phase 1 | 19 | 3B Pharmaceuticals GmbHINDUSTRY | 2 | Aug 24, 2025 | clinicaltrials |
| NCT07066982 | Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas(BAH2573-103) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT02657005 | TK216 in Patients With Relapsed or Refractory Ewing Sarcoma | terminated | Phase 1 / Phase 2 | 85 | Oncternal Therapeutics, IncINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03373097 | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 42 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT02076906 | MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors | completed | Phase 1 | 7 | AeRang KimOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03604783 | Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors | terminated | Phase 1 | 74 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05093322 | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 13 | HutchmedINDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials